2011年6月22日 · One frequently reads that an adverse effect may occur if a certain drug is given to someone who is already taking cyp3a inhibitors or inducers. Answer this question The information on this page reflects personal experiences shared by our community members.

2025年2月3日 · Avoid using this medicine with strong or moderate CYP3A inducers. CYP3A substrates: If Journavx is used together with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, then you should refer to the Prescribing Information for the CYP3A substrates for dosing instructions.

2024年3月12日 · Use of CERDELGA is contraindicated, to be avoided, or requires dosage adjustment in patients taking CYP2D6 or CYP3A inhibitors, depending on CYP2D6 metabolizer status, type of inhibitor, or degree of hepatic impairment [see Dosage and Administration (2.3), Contraindications (4), Drug Interactions (7.1)].

2025年2月6日 · Adverse Reactions with Concomitant Use with CYP3A Inhibitors: Concomitant use with strong or moderate CYP3A inhibitors increased vanzacaftor, tezacaftor, and deutivacaftor exposure, which may increase the risk of ALYFTREK associated adverse reactions. Reduce the ALYFTREK dosage with concomitant use.

2025年2月26日 · PAXLOVID which includes nirmatrelvir, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro: also referred to as 3CL pro or nsp5 protease) inhibitor, and ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor, is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high …

2025年2月26日 · CYP3A Substrates. The plasma levels of simvastatin, a CYP3A substrate, and its active metabolite are increased by 100% in healthy volunteers receiving 80 mg once daily and RANEXA 1000 mg twice daily [see Drug Interactions (7.2)]. Mean exposure to atorvastatin (80 mg daily) is increased by 40% following co-administration with RANEXA (1000 mg ...

5 天之前 · Cautions for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Contraindications. Concomitant use with drugs highly dependent on CYP3A for metabolism and for which elevated plasma concentrations are associated with serious and/or life-threatening events (e.g., alfuzosin, ergot alkaloids, lovastatin, lurasidone, oral midazolam, pimozide, …

2024年5月10日 · If concomitant use of a moderate CYP3A inhibitor cannot be avoided, reduce olaparib dosage to 150 mg twice daily. If concomitant use of CYP3A inhibitor is discontinued, return olaparib dosage to the dosage used prior to initiation of the CYP3A inhibitor (after 3–5 terminal half-lives of the CYP3A inhibitor). Special Populations Hepatic Impairment

2025年2月10日 · Concomitant use of potent CYP3A inducers that can significantly reduce nirmatrelvir or ritonavir plasma concentrations and result in potential loss of virologic response and possible resistance; these drugs include, but are not limited to, apalutamide, carbamazepine, phenobarbital, primidone, phenytoin, lumacaftor/ivacaftor, rifampin ...

2024年11月10日 · Avoid concomitant use of TUKYSA with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage in accordance with approved product labeling. P-glycoprotein (P-gp) Substrates. Clinical Impact